Company Performance Metrics
- Paul Blum: CEO and Co-Founder
Marina Blum: Operations Manager
Neurocarrus is developing a new way to treat human pain. Using protein engineering, they created a novel, non-opioid therapeutic that targets sensory neurons to “freeze” pain signals before they ever get to the brain. Promising laboratory and animal model findings show that their therapeutic, N-001, lasts longer than opioids while providing
equivalent pain relief. Their mission is to improve the quality of life for people suffering from chronic pain and at the same time, provide an urgently needed alternative to addictive opioids in the midst of the raging national epidemic.
In addition, N-001’s unique drug delivery platform holds great promise for partnership with other therapies or identification needs related to sensory neurons. Neurocarrus has an exclusive license to both our drug and the delivery system for all fields of use.
